

Ajanta House, Charkop, Kandivli West, Mumbai 400 067 India

F +91 22 6606 1200 E info@ajantapharma.com

T +91 22 6606 1000

W www.ajantapharma.com

10th September, 2018

National Stock Exchange of India Exchange Plaza, 5th Floor, Plot no. C/1, G Block Bandra Kurla Complex, Bandra (East) Mumbai – 400 051

Scrip Code: NSE – AJANTPHARM EQ

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001

Scrip Code: AJANTPHARM 532331

Ref: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sub.: Scheme of Amalgamation and Arrangement between Gabs Investments Private Limited and Ajanta Pharma Limited and their respective shareholders ("Scheme")

Dear Sir/Madam,

With reference to the subject matter, we would like to inform that the Hon'ble National Company Law Tribunal, Mumbai Bench ('NCLT') did not deem it fit to approve and sanction the proposed Scheme. The copy of the order pronounced by the Hon'ble NCLT was made available to the Company by the Counsel of the Company on 7th September, 2018.

The Company is examining the order in detail.

This is for your information and records.

Thanking You,

Yours faithfully,

Gaurang Shah

AVP - Legal & Company Secretary